GlaxoSmithKline and Sanofi on Monday announced a new Phase 2 trial involving their protein-based COVID-19 vaccine candidate after facing a setback in December. The companies had said that previous tests had seen insufficient immune responses in older people, which sent them back to the drawing board.

In a news release Posted on Monday, the companies announced the launch of a new Phase 2 study involving 720 volunteers between the ages of 18 and 18, which they hope will help determine the appropriate antigen dose for Phase 3 evaluation .


“Over the past few weeks, our teams have worked to refine the antigen formulation of our recombinant-protein vaccine, based on lessons learned from our early phase 1/2 study,” by Thomas Triumph, executive vice president and Sanofi Kastur Chief, Said in the news release. “We believe our vaccine candidate has strong potential and we are greatly encouraged by the latest preclinical data. This new Phase 2 study will enable us to identify the ultimate vaccine formulation for adults of all ages. We focused on our commitment Has demonstrated its commitment to. And the ability of the global fight against pandemics, and this new study gives us a step towards achieving our primary goal of developing a COVID-19 vaccine with a good efficacy and safety profile. Takes R. “

South Africa coronaryvus variants detected in New York resident

Companies hope that if the test results are positive, Phase 3 could begin in the second quarter of 2021, with the vaccine being put on track to be available in the fourth quarter.

Click here for complete coronary coverage

The news release said that Sanofi has started development work against the new variants.